European Medicines Agency finds no signal for decreased effectiveness of HBVAXPRO and Procomvax

View source ↗

Summary

The EMA reports no evidence of decreased effectiveness for the hepatitis B vaccines HBVAXPRO and Procomvax following investigations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• HBVaxPro (Hepatitis B surface antigen, recombinant)
• Procomvax